Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — August 2018

Planlagt Fastgjort Låst Flyttet Genmab
2.0k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • G Offline
    G Offline
    gentogen
    wrote on sidst redigeret af
    #16

    Det fremgår af hjemmesiden for HOVON, af CD20xCD3 rekrutterer fra foreløbig en klinik i Rotterdam (for lige at følge op på iagttagelsen fra tidligere)

    1 Reply Last reply
    0
    • G Offline
      G Offline
      gentogen
      wrote on sidst redigeret af
      #17

      De har en undergruppe, der arbejder med 'first-in-man' studier

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #18

        so you think this is GCT3013-01 @gentogen ?

        1 Reply Last reply
        0
        • R Offline
          R Offline
          Raffles
          wrote on sidst redigeret af
          #19

          Thanks Bulder, EL and Gentogen. Your input is highly appreciated:-)

          1 Reply Last reply
          0
          • G Offline
            G Offline
            gentogen
            wrote on sidst redigeret af
            #20

            Det ved jeg med sikkerhed, at det er. Se EHA 23 Abstract: PF637 fra juni måned, hvor det hedder, at "The clinical safety of DuoBody-CD3xCD20 (GEN3013) in patients with B cell malignancies will be assessed in a first-in-human study."

            1 Reply Last reply
            0
            • G Offline
              G Offline
              gentogen
              wrote on sidst redigeret af
              #21

              CD3 BISPECIFIC ANTIBODY SCREEN IDENTIFIES CD20 AS THE MOST EFFICIENT TARGET FOR ELIMINATION OF B CELL MALIGNANCIES; PRE-CLINICAL EVALUATION OF DUOBODY-CD3XCD20
              Author(s): Patrick Engelberts , Ida Hiemsta , Joyce Meesters , Bart De Jong , Theodora Salcedo , Sandra Verploegen , Edward van den Brink , Danita Schuurhuis , Sjeng Horbach , Aran Labrijn , Paul Parren , Janine Schuurman , Esther Breij
              EHA Learning Center. Engelberts P. Jun 15, 2018; 215079

              1 Reply Last reply
              0
              • G Offline
                G Offline
                gentogen
                wrote on sidst redigeret af
                #22

                one of the CD3xCD20 BsAbs showed extraordinary potency and outperformed the other CD20-targeting BsAb as well as CD3 BsAbs against all other B cell targets tested. This BsAb, designated DuoBody-CD3xCD20, was shown in vitro to only activate T cells in the presence of B cells and to induce potent T-cell-mediated cytotoxicity of B cell lymphoma cell line

                1 Reply Last reply
                0
                • G Offline
                  G Offline
                  gentogen
                  wrote on sidst redigeret af
                  #23

                  https://learningcenter.ehaweb.org/eha/2018/stockholm/215079/patrick.engelberts.cd3.bispecific.antibody.screen.identifies.cd20.as.the.most.html?f=ce_id=1346*ot_id=19042*media=3

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #24

                    excellent

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #25

                      you know, some still think PI stands for ProInvestor, but I think Helge really meant Private Investigator lol

                      1 Reply Last reply
                      0
                      • Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktør
                        wrote on sidst redigeret af
                        #26

                        😄

                        1 Reply Last reply
                        0
                        • R Offline
                          R Offline
                          Raffles
                          wrote on sidst redigeret af
                          #27

                          lol EL:-) And we have a number of Sherlock Holmes amongst us! Well done.

                          1 Reply Last reply
                          0
                          • BulderB Offline
                            BulderB Offline
                            Bulder
                            wrote on sidst redigeret af
                            #28

                            Tak gentogen. Gad vist om det er den "dæmpning" af cd3-armen, som Winkel snakkede om, som kun aktiverer T-celler, når der er (maligne) B-celler til stede?

                            1 Reply Last reply
                            0
                            • BulderB Offline
                              BulderB Offline
                              Bulder
                              wrote on sidst redigeret af
                              #29

                              Lyder også lovende rent safety-mæssigt, at sc versionen "demonstrated lower peak cytokine levels".

                              1 Reply Last reply
                              0
                              • JørgenVarnæsJ Offline
                                JørgenVarnæsJ Offline
                                JørgenVarnæs
                                wrote on sidst redigeret af
                                #30

                                Det er vel den egentlige nøgle til cd3cd20 koden

                                1 Reply Last reply
                                0
                                • SolsenS Offline
                                  SolsenS Offline
                                  Solsen
                                  wrote on sidst redigeret af
                                  #31

                                  Har en linket til Hovon ?

                                  1 Reply Last reply
                                  0
                                  • SolsenS Offline
                                    SolsenS Offline
                                    Solsen
                                    wrote on sidst redigeret af
                                    #32

                                    Godt arbejde !

                                    1 Reply Last reply
                                    0
                                    • G Offline
                                      G Offline
                                      gentogen
                                      wrote on sidst redigeret af
                                      #33

                                      Se punkt 3 samt linket i slutningen af det punkt (inklusionskriterier): http://www.hovon.nl/working-groups/working-groups/llpc.html

                                      1 Reply Last reply
                                      0
                                      • SolsenS Offline
                                        SolsenS Offline
                                        Solsen
                                        wrote on sidst redigeret af
                                        #34

                                        Tak det prøver jeg

                                        1 Reply Last reply
                                        0
                                        • P Offline
                                          P Offline
                                          peter12
                                          wrote on sidst redigeret af
                                          #35

                                          Jeg ved ikke om det er nyt at MOR202 udvikling i MM bliver stoppet ? https://www.morphosys.com/media-investors/media-center/morphosys-ag-reports-second-quarter-2018-financial-resultshttps://www.morphosys.com/media-investors/media-center/morphosys-ag-reports-second-quarter-2018-financial-results

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger